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I. Introduction
As dental implant surgery for edentulous patients became a gold standard, bone grafts such as guided bone regeneration and sinus lift were widely operated in Korean dentist. There has been increased in the number of bone substitute products available to the dental clinician. Still the autologous bone is considered to gold standard, because of its three properties with osteoconduction, osteoinduction and osteogenesis. Osteogenesis is, the property of autogenous graft, generation of new bone from osteogenic cells within the graft. Osteoinduction is the property of the autogenous graft, allogenic graft and intrinsic bone matrix proteins such as transforming growth factor and bone morphogenetic proteins (BMP) to recruit of host stem cells. Osteoconduction is the property of a mechanical structure with biocompatibility for the migration of osteogenetic cells 1, 2 . Allograft has been widely used and is an attractive alternative as it avoids donor site morbidity. It has the following advantage: (1) donor site is not needed, (2) abundant supply, and (3) little risk of transmission of infectious diseases 3 . The ideal alloplastic bone substitutes is biologically stable and maintain its volume with allowing cell infiltration and remodeling process 4 . The alloplastic bone substitutes has various osteoconductive capabilities depending on the manufacturing methods, crystal structure, size of pores, mechanical properties, composition and absorption rate 5 . Hydroxyapatite (HA) is the main mineralized of bone tissue and it exerts an osteoconductive ability when grafted in the defect. Synthetic calcium phosphate ceramics (β-tricalcium phosphate [β-TCP] and HA) could be altered to autogenous graft, allogenic graft and xenogenic graft and it was used as block, cement, pastes, powder, granules and putty type with carboxymethyl cellulose or hyaluronic acid 6 . In Korea, the development of implant dentistry has led to the development of many dental synthetic bone substitute in many domestic companies.
As dental implant surgery for edentulous patients became a gold standard, bone grafts such as guided bone regeneration and sinus lift were widely operated in Korean dentist. All bone substitutes used commercially in Korea are firstly evaluated by the Ministry of Health and Welfare (MOHW) for safety and efficacy of the product. They are commercialized after being priced, classified, and registration by the Health Insurance Review and Assessment Service (HIRA). The post-application management is obligatory for the manufacturer (or representative importer) to receive a certificate of Good Manufacturing Practice (GMP) by Ministry of Food and Drug Safety (MFDS).
According to Korea Food and Drug Safety (KFDS) No. 2016-156 of 'medical device manufacturing and quality control standards', after the approval of commercially use, the manufacturer or importer is required to renew the conformity certification every three years or immediately if the information of product changed 7 . If any information of the product changed, the certificate of conformity should be issued or reissued by the manufacturer or the importer. Therefore, the manufacturer or importer of registered in the MFDS could be important factors in terms of quality control of currently available bone substitutes.
However, it is difficult for clinicians to know whether the certification or the quality of product is properly managed. Therefore, the purpose of this study is to analyze ingredients, manufacturers, importers, current status and reference levels of dental synthetic bone listed in MOHW notification No. 2018-248.
II. Materials and Methods
Commercially available dental alloplastic bone substitute which was approved MOHW notification (No. 2018-248) 8 is analyzed the details of manufacturer, importer, composition, available form, Food and Drug Administration (FDA, USA) approval. This review of literature included studies that detailed the use of bone graft substitute in dental situation, animal, in vivo, and in vitro studies. We excluded studies in the orthopedic and neurosurgery field and those not published in English or Korean. The Google Scholar, ISI Web of Knowledge, PubMed, EMBASE and Cochrane Databases were searched in February 2019 using the criteria of registered or trademarked product name. The authors read the full text of the studies and classified it according to the 'level of evidence' presented by Wright et al. 9 . (Table 1) Human study level I evidence is a prospective, randomized, or splint-mouth study with definite results that support the use of alloplastic bone substitute in clinical condition. The case report was classified as level IV. Clinicial studies used alloplastic bone substitute as carrier of osteoinductive growth factors or as comparison of membrane efficacy have not been evaluated for osteoconductive capacity, but have been assigned to human study level IV as showing clinical stability. The animal, in vivo, and in vivo study were separately indicated. All authors reviewed each paper and independently assigned evidence levels. If there is a disagreement on the assigned level, discussion and resolution were made. All studied with human study level I, II, III, or IV were included to be citation 10 .
III. Results
In December 2018, thirty-seven dental alloplastic substi- (Table 2) The researches, however, were not published and the authors could not include in this review. The available information regarding the delivery form, component, indications, morphology (porosity, biomechanical structure, particle size), and property are shown in Tables 3 to 8.
The products approved in FDA
Seven products were approved in FDA [11] [12] [13] [14] [15] [16] [17] . (Table 2 The details of dental alloplastic bone substitute which was approved by MOHW notification No. 2018-248 were analyzed 8 . (Table 3 ) Among them, BIO-C and OssPol-dental were officially discontinued. CollaOss (SK Bioland, Cheonan, (Table 3) CollaOss is listed as a dental synthetic bone in the MOHW and HIRA data. Although it was represented as xenograft in the journal [18] [19] [20] [21] ; however, it was included in this review. (Table  3) There are three products that do not match in the component registered in MOHW: (1) Cerasorb M granules (99% β-TCP not β-TCP combined with HA; Curasan), (2) FRAB-ONE-Inject (Inobone, Cheonan, Korea: hyaluronic acid addition with HA+β-TCP), and (3) TCP Dental (99% β-TCP not 95% β-TCP combined with 5% HA). (Table 3) As a result, out of the 33 dental bone substitutes that are currently registered in MOHW and HIRA, 28 products could be commercially available when considering the products that are different form registered information as below: Excelos (TCPGLD) and Excelos (TCPGMD, TCPGLD) are sold exclusively by Excelos, Mega-TCP (CGL) and Mega- 3. Analysis of dental alloplastic bone substitutes according to constituents
The main components of dental alloplastic bone substitute are tricalcium phosphate (Ca 3 (PO 4 ) 2 , β-TCP), calcium phosphate (CaP), and hydroxiapatitie (Ca 10 (PO 4 ) 6 (OH) 2 , HA) which is crystalline form of CaP. (Table 4) 1) Dental alloplastic bone substitutes consist of hydroxyapatite HA is an inorganic material which account for 65% of bone matrix and can be classified as dense and porous, sintered ceramic and non-ceramic, and bovine, coralline and synthetic depending on the origin. Typical characteristics are as below.
(1) As large as the particle size, it remains for a long time with slow absorption. (2) The higher the porosity, the easier the penetration of new bone and the quicker absorbed. (3) The larger the crystallinity, the longer the absorption period. (4) Rigid and dense block-form products have high compressive strength but are susceptible to fracture. (5) The higher the porosity, the lower the strength 5 . Among the dental alloplastic bone substitutes allowed for use in Korea, there were four products that consisted of HA. OssaBase-HA (LASAK, Praha, Czech) has a retrospective study of guided bone regeneration in 2018, but it was obtained human study level IV due to a poor study design 22 . However, many other animal, in vivo, and in vitro studies for osteoconductivity [23] [24] [25] [26] . No journals were found for Ovis BONE HA (DENTIS, Seoul, Korea). CollaOss consists of 90% porcine-deriven HA and 10% porcine deriven collagen. It was classified as alloplastic graft in MOHW and HIRA, on the other hands, it was introduced as xenograft in many studies [18] [19] [20] [21] . In the manufacturer (SK Bioland), it is commercially available in plug type and putty type. In comparison with the collagenated bovine bone (Bio-Oss collagen; Geistlich Biomaterials, Woulhusen, Switzerland) into the extraction socket, it was received the human study level III because there was no difference in the efficacy 18 . Human study level IV was received in a clinical study to comprare the effects of membranes on peri-implant defect 19 . Animal studies showed osteoconductivity 20, 21 . (Table 4) 2) Dental alloplastic bone substitutes consist of tricalcium phosphate TCP has a composition of calcium and phosphorus in ratio of 3 and 2. It was known as partially transition into HA and absorption in vivo, but various absorption periods of three to 24 months have been reported depending on the products. The rate of absorption varies according to the chemical structure, porosity and particle size of the material 5 . The general characteristics suggested by the manufacturer of TCP are as follows. (1) Use with platelet-rich plasma is effective. (2) It is absorbed at the same time as new bone graft. (3) Due to the interconnection of the pores, bone fibers are rapidly penetrated and could promote the regeneration. (4) Since the particle is rounded, there is little mechanical irrigation in surrounding tissues and little inflammatory reaction. (5) High mechanical stability prevents early collapse and inhibits undesirable macrophage activity.
Of the approved products for Korean dental alloplastic bone substitute, seven products that consist with TCP were commercialization. BoneSigma TCP (SigmaGraft, Fullerton, CA, USA) has been described as one of the in vitro studies 27 , and clinically available products 28, 29 but no clinical studies have been published. Excelos is registered as β-TCP etc. in MOHW and has two types of powder and injection and registered. Injection type is a mixture of biodegradable polymers such as poloxamer and hydroxypropyl methylcellulose (HPMC) to enhance injectable property, moldability and hemostasis. A clinical study comparing putty type Excelos with extraction and using as BMP carriers received a human study level IV 30 . Excelos has animal studies for BMP carrier 31, 32 and in vivo study for osteoconduction 33 . No journals were found for Mega-TCP. Sorbone (META-BIOMED, Cheongju, Korea) was validated and received human study level II by a split-mouth study as a control of cockle-shell bone substitute in socket preservation 34 , and used as a control material for the effect of alendronate on periodontal intra-osseous defect 35 . SynCera (Oscotec, Seongnam, Korea) had animal and in vivo study for osteoconductivity 36, 37 . Cerasorb was approved by the FDA and commercially available to Cerasorb M which reduced porosity from 80% to 65%
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. It was received human study level I by randomized controlled trial and systematic review that was equivalent to an autogenous graft in sinus lift 38, 39 . It was received human study level III in cystic lesion, periodontal defect and cleft alveolus 40 . Also, as a result of histologically sufficient alveolar bone regeneration, human study level III was obtained in extraction socket 41 . As human study level IV, it was used with an enamel matrix derivative in the periodontal defect 42, 43 , peri-implant defect after immediately implantation after extraction 44 , every lots of animal, in vivo, and in vitro studies for osteoconduction 6, [45] [46] [47] [48] [49] [50] [51] [52] [53] [54] [55] [56] . TCP Dental was registered as 5% of HA and 95% of β-TCP in MOHW and HIRA. However, the manufacturer (Kasios SAS) and importer (B.IMTECH, Yongin, Korea) advertised as 99% of β-TCP. Many studies and FDA 510(k) also represented as β-TCP 17, [57] [58] [59] [60] [61] [62] [63] [64] [65] . It was received human study level III by successful histologic and clinical result comparing Xenograft (BonePlus-xs; Integros, Adana, Turkey) in sinus lift 57 . Animal, in vivo, and in vitro studies for osteoconductivity [58] [59] [60] [61] [62] [63] [64] [65] .
3) Dental alloplastic bone substitutes consist with hydroxyapatite and tricalcium phosphate The mixing ratio of HA and TCP varies from 2:8 to 7:3. It has the following characteristics.
Boncel-Os (CGbio) consists with 30% of HA and 70% of β-TCP. It was introduced as one of the clinically available products 66 , and there is an animal study used as a BMP carrier 56 . BoneSigma BCP (SigmaGraft) consists with 60% of HA and 40% of β-TCP. In vivo study has been published that . Dualpore Collagen D-Putty was registered as 60% of HA, 0.3% of bovine-derived collagen, and 39.7% of distilled water by the MOHW and HIRA. On the other hand, the manufacturer (OssGen) advertised the product as 60% HA and 40% β-TCP in 94.5% of biphasic CaP, and with an additional 5.5% bovine collagen but there are no reports of any evaluations of the evaluating its information provided. In MOHW and MFDS, Inobone has registrated its products as FRABONE DENTAL and FRABONE DENTLA INJECT, but they are commercially available as FRABONE and FRABONE-Inject. FRABO-NE (Inobone) consists with 60% of HA and 40% of β-TCP and it was received patent in USA, Germany, and Korea as mimic the harversian canal structure 68, 69 . FRABONE-Inject (Inobone) is a product of hyaluronic acid addition to FRAB-ONE, which advertised to increase moldability and absorption rate by act as soluble granules of hyaluronic acid. However, there was no related researched were found. GENESIS-BCP (DIO, Busan, Korea) consists with 60% of HA and 40% of β-TCP. It was received human study level II by prospective controlled clinical trial which results good outcome in periodontal defect 70 . In horizontal augmentation, it was showed successful result with NanoBone (HA and silica gel matrix; Artoss GmbH, Warnemünde, Germany) in case report and it obtained human study level IV 71 . There were many animal, in vivo, and in vitro studies for osteoconductivity [72] [73] [74] [75] [76] [77] . Manufacturers have the two types of MBCP as combination of HA and β-TCP as ratio as 60:40 and 20:80, and a moldable MBCP (In'Oss) made by mixing hydrogel to MBCP. However, represented importer (Purgo Biologics, Seongnam, Korea) only has granule or syringe type of MBCP+ which consists with 20% of HA and 80% of β-TCP. MBCP and MBCP+ were received in FDA 510(k) approved 12, 16 . There were many clinical studies from MBCP which consists with 60% of HA and 40% of β-TCP [78] [79] [80] [81] [82] [83] [84] . On the other hand, MBCP+ was published only animal studies [85] [86] [87] [88] and in vitro studies 89, 90 .
Although not introduced as MBCP+, a combination of 20% of HA and 80% of β-TCP was as same resorption and bone growth as combination of 60% of HA and 40% of β-TCP in retrospective clinical trial for extraction socket and it could be human study level IV 84 . Newbone (GENOSS) consists with 20% of HA and 80% of β-TCP. Although there were animal and in vivo studies for osteoinductivity [91] [92] [93] , no clinical studies were found. Boncel-Os consists with 30% of HA and 70% of β-TCP. It was introduced as one of clinically available products 66 and used as BMP carrier in animal study 56 . OSTEON series (GENOSS) were available as vial, sinus, . OSTEON consists with 70% of HA and 30% of β-TCP. In retrospective clinical study for sinus lift, OSTEON alone could result welldeveloped lamellar bone as same as Xenograft (Bio-Oss; Osteohealth, Shirley, NY, USA) and it could be received human study level III 94 . There were many animal and in vivo studies for osteoconductivity [95] [96] [97] [98] . OSTEON II consists with 30% of HA and 70% of β-TCP. In retrospective clinical study for extraction socket, OSTEON II and OSTEON II Collagen were significantly more effective than collagen or native defect and the histological result was shown in animal studies 99 . Therefore, it could be received human study level III in extraction socket. It was received human study level IV by retrospective study as control group for sinus lift 100 , 6 months after vertical augmentation which particulated OSTEON II was showed no significantly difference on volume change and peri-implant marginal bone loss compared with autogenous block and allogenous block bone 101 , successful results on clinical and histologically in ridge augmentation 102, 103 , successful outcome on graft after implant removal 104 , and clinically effective on periodontal defect 105 . Many animal and in vivo studies for osteoconductivity [95] [96] [97] 106, 107 . OSTEON III consists with 60% of HA and 40% of β-TCP. There was animal study as BMP carrier 108 . Although there was no OSTEON III Collagen related study, OSTEON II Collagen had animal and in vivo studies for osteoconductivity 109, 110 . Ovis BONE BCP (DENTIS) consists with 20% of HA and 80% of β-TCP. No journals were found for Ovis BONE BCP. Q-Oss+ (OSSTEM IMPLANT, Seoul, Korea) consists with 20% of HA and 80% of β-TCP. It was received human study level IV by the clinical study on peri-implant defect 111 . There were in vivo study for osteoconductivity 112 TOPGEN-S (Toplan, Seoul, Korea) consists 20%
of HA and 80% of β-TCP and there could not be found for journals for TOPGEN-S.
4) Dental alloplastic bone substitutes consist with CaP (composition not confirmed) INNO-CaP (Cowellmedi) was advertised that consists CaP, however, the composition was not cleary known and no relevant research were found.
IV. Discussion
Commercially available dental alloplastic bone substitute which was approved MOHW notification No. 2018-248 were broadly divided into 4 groups as C group (bone union and fixation group), L group (general materials), T group (human tissue), and non-insurance group. In the subcategory, there were C0 group (bone substitutes: xenograft, alloplastic graft), L7 group (dental material: dental xenograft, dental alloplastic graft), TB group (bone, demineralized bone matrix, bone block, bone chip, bone powder), non-insurance group (treatment material, human-derived bone, bone substitute containing bone morphogenetic protein [rhBMP-2]) 8 . Among them, dental alloplastic bone substitutes in L7 of L group were included in this study.
The post-application management is obligatory for the manufacturer (or representative importer) to receive a certification of GMP by MFDS. According to FKDS No. 2016-156 of 'medical device manufacturing and quality control standards', the certification of GMP of human tissue or functional replacement product should be renewed every three years in article 9. According to article 10 of KFDS No. 2016-156, the certification of GMP should be reissued when any information for the products changed (change of the name of the importer or manufacturer, change of location of the importer or manufacturer). In article 12 and 15, the quality control examination agency reports periodic on the compatibility of medical device to director of KFDA 7 . Therefore, the manufacturer or importer of registered in the MFDS could be important factors in terms of quality control of currently available bone substitutes.
However, nineteen products (51.4%) were different information among the 37 products registered in MOHW. Four products (10.8%) were different registered ingredients from journal or advertisement including DualPor COLLAGEN D-PUTTY (OssGen), Cerasorb M granules, FRABONEInject, and TCP Dental. Nine products (24.3%) were differ in product name or not available including CollaOss (Syringe), Mega-TCP (CGL), Cerasorb, Cerasorb M granules, BIO-C, Excelos (TCPGMD, TCPGLD), MBCP Plus (Biometlante), OssPol DENTAL, and OSTEON Sinus. Especially, CollaOss (Block) and CollaOss (Putty) were registered as dental alloplastic bone substitute in MOHW but they were introduced as xenograft in advertisement and journals. Five products (13.5%) had different manufacturer or importer including Excelos Inject (CGbio), Excelos (TCPGLD), Excelos (TCP-GMD, TCPGLD), Mega-TCP (CGM, CGL), Boncel-Os.
For a successful clinical outcome, it cannot be overemphasized that the quality of the materials or medical device should be constant and strictly controlled. Unfortunately, it is hard to identify the certification of GMP or to verify the quality in every clinical situation. Therefore, it is necessary to leave certificate to the government agency or the company which is responsible for the product. In addition the related dental institute or academy should to consider the security on quality of the product.
Implant dentistry has become a common treatment in Korea, many studies and development have been made on implant and bone graft materials. Among dental alloplastic bone substitutes which were registered in MOHW, twentynine (78.4%) products were domestically produced, of which three out of seven approved by FDA were made in Korea [11] [12] [13] [14] [15] [16] [17] . However, there are only ten products (27.0%) have been published with clinical study, of which six are Korean products. In the view of reference, the reference level could not be as directly same as the efficiency of the product, but it could be the basis of product selection for the clinician since minimal safety and efficiency can be regarded as verified. Reference level I received Cerasorb M (β-TCP 99%) as a sinus lift 38, 39 . Reference level II received Sorbone (β-TCP 100%) in extraction socket and periodontal defect 34, 35 , GENESIS-BCP (β-TCP 40% and HA 60%) in periodontal defect 70 . Reference level III received Cerasorb M (β-TCP 99%) in cystic cavity, periodontal defect, cleft defect and extraction socket 40, 41 , CollaOss (HA 90% and collagen 10%) in extraction socket 18 , OSTEON (β-TCP 30% and HA 70%) in sinus lift 94 , OSTEON II (β-TCP 70% and HA 30%) in sinus lift 99 , TCP Dental (β-TCP 99.9%) in sinus lift 57 . Reference level IV is insufficient to verify the efficiency, could be seen as a step that clinically confirms safety. Cerasorb M was in peri-implant and periodontal defect [42] [43] [44] , CollaOss was in peri-implant defect 19 , OssaBase-HA (HA 100%) was in guided bone regeneration 22 , Excelos (β-TCP 100%) was in extraction socket 30 , MBCP+ (β-TCP 80% and HA 20%) was in extraction socket 84 , GENESIS-BCP was in ridge augmentation 71 , OSTEON II was in sinus lift 100 , ridge augmentation [101] [102] [103] , periodontal defect 105 achieved for reference level IV. In addition, there were many animal, in vivo, and in vitro studies for osteoconductivity or role as carrier of osteoinductive growth factors or control material. In order to obtain MOHW and MFDS approval for commercial use in Korea, a data based on research or experiments should be required, but these data could not be included in this study because they were not publicly available. Because dental bone graft surgery has been performed in various environments such as sinus lift, ridge augmentation, cystic lesion, periodontal defect, peri-implant defect, extraction socket, it could be difficult to obtain high reference level in all dental bone grafting fields. However, it is nevertheless necessary to demonstrate the clinical level of Korean dental operation and the development level of bone graft substitutes.
In conclusion, there is not enough information about the effectiveness and safety of currently available alloplastic bone substitute in dental performance. Further clinical trials including well designed RCTs are necessary to evaluation the clinical efficacy of dental alloplastic bone substitutes in Korea. It should be aware of the limited information and developed the clinical evidences and regulations for clinicians.
